A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA
Summary
- Eligibility
- for people ages 18-100 (full criteria)
- Location
- at La Jolla, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Srila Gopal, MD
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSD
- Srila Gopal, MD
Associate Physician, Medicine. Authored (or co-authored) 12 research publications. Research interests: Anemia · Sickle Cell Anemia · Thalassemia · Hemophilia · Thrombosis · Novel Therapeutics.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Rigel Pharmaceuticals
- ID
- NCT03764618
- Phase
- Phase 3
- Study Type
- Interventional
- Last Updated